The 58th Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology

Cezmi Akdis

Director of the Swiss Institute of Allergy and Asthma Research (SIAF), Davos,
Ordinarius Professor in Zurich University Medical Faculty, and one of the directors of the Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. Medical degree Uludag University Medical Faculty, Bursa Turkey in 1985. Specialized on Infectious Disease and Clinical Microbiology 1991, Immunology 1994 in Uludag University, Venia Legendi (Habilitation) University Zurich 2001, Professor University Zurich 2006.

Publications:
ORCHID ID: 0000-0001-8020-019X
GOOGLE SCHOLAR ID: Cezmi Akdis
Articles in peer-reviewed journals: 540; editorial articles: 26; unreviewed publications and book chapters: 112; total impact factor of publications: 3811.6; total number of citations: 40’673 average citation per article: 54.04; h-index: 108; first or last author articles cited more than 100 times 90. Thomson Reuters (Clarivate) highly cited author: 2016-2017-2018-2019-2020.

Academic: President of the European Academy of Allergy & Clinical Immunology (14’000 members) between 2011-2013. Executive Committee Member between 2003-2015 and Vice President between 2007-2011. Editor of three Global Atlases. Allergy (written by an international group of 183 opinion leaders, and includes 274 illustrations and 100 tables), Asthma (written by an international group of 80 opinion leaders, and includes 147 illustrations and 46 tables) and Allergic Rhinitis and Chronic Rhinosinusitis (written by an international group of 218 opinion leaders, and includes 269 illustrations and 92 tables). These atlases have been downloaded more than 130’000 copies and 25’000 copies distributed in print. They are translated to Chinese, Spanish, Greek, Portuguese, Russian.
Associate Editor 2007-2015 Journal of Allergy and Clinical Immunology
Co-Editor-in-Chief 2015-2017 Journal of Allergy and Clinical Immunology
Editor-in-Chief of Allergy 2018 January- present

Organizational: Founder and organizer of World Immune Regulation Meetings, Davos I-XIV (600-1000 participants). One of the founders and Past Chair of International Coalition in Allergy and Asthma (iCAALL), a presidents’ network between 4 main organizations in the area of allergy and clinical immunology, European Academy, American Academy, American College and World Allergy Organization, and one of the founders and executive committee member of Global Allergy and Asthma European Network (GA²LEN). Ex-Com European Academy of Allergy Clin Immunol 2003-2015, SPC Chair 2005-2007, Vice President 2007-2011, President 2011-2013

Major discoveries from his research group:
Immune regulation and allergen tolerance, plasticity of antigen-specific T cells 1995, human T regulatory cells 1996, immune suppressive role of histamine receptor 2 2000, human Type 2 NK cell subset 2001, human regulatory NK cells 2007, regulatory innate B cell subset 2017, regulatory innate lymphoid cells 2019.
Epithelial barrier hypothesis studies: Mechanisms of eczema 2000, mechanisms of epithelial shedding in asthma and chronic rhinosinusitis 2003, endotypes of asthma, chronic rhinosinusitis and atopic dermatitis 2011, epithelial barrier hypothesis for the development of allergic and autoimmune diseases 2017, major environmental changes after 1960s and their effects on the immune system 2019. More than 60 publications and a work of 20 years.
Adenylcyclase activating suppressor G-protein coupled receptors; immune regulation by histamine and microbiota 2000- present. More than 30 publications on COVID-19, pathophysiology, risk factor, severity, patient characteristics, how to handle allergy and asthma patients during pandemic.

Honors: Honoured with several international honors and awards, such as Ferdinand Wortman Prize, 1996; Hoechst Marion Roussel Award, 1998; Professor Hans Storck Award, 1998; Dr.-Karl Heyer-Preis, 1998; Sedat Simavi Medicine Award, 1998; Allergopharma Award, 2001; European Allergy Research “Gold Medal”, 2004; TUBITAK Exclusive Award, 2007; BUSIAD Award 2012; World Allergy Organization Award, 2013; AAAAI, Elliott Middleton Memorial Lecture, 2014; European Federation of Immunology Societies, World Immunology Day Lectures, 2014 and 2017; Honors given by the Ozbekistan Academy of Sciences, 2015 and Capital University of Beijign, 2015, Swiss Society of Allergy Immunology, 2017. Honorary Professor in Capital Medical University, National Tongren Hospital, Beijign Institute of Otolaryngologology, China. Senate Member of the Swiss Academy of Medical Sciences. Honorary Member of the Swiss Society of Allergy Immunology (SGAI-SSAI) and Honorary Member and Fellow of the European Academy of Allergy and Clinical Immunology, Robert Goltz Lecture, Minneapolis University 2019, Kantonal Anerkkennungs Prize, Canton of Grissons 2020, Honorary Professor in Wuhan University 2020, AAAAI: Harold Nelson Memorial Lecture.

Linked in: linkedin.com/in/cezmi-akdis-05875667

CLOSE

Erik Wambre

Benaroya Research Institute
Dr. Erik Wambre is an Associate Member and Director of the Clinical Immunology and Translational Research program at the Benaroya Research Institute at Virginia Mason in Seattle, Washington. Dr. Wambre was born and raised in France. He received his MS degree in Molecular Biology from the University of Lille in 2003 and his Master of Business Engineering (MBE) from the Ecole de Biologie Industrielle (Cergy) in 2004. He then attended the University Pierre & Marie Curie (Paris 6) in 2008, where he earned his PhD in Immunology. Dr. Wambre joined the Benaroya Research Institute in 2009 to complete a postdoctoral fellowship. He subsequently became an Assistant Member in 2013 and more recently promoted to Associate Member in 2019.

Dr. Wambre’s research is focused the application of in depth immune monitoring of antigen-specific T cell responses in the development of allergy, asthma and cancer vaccines. The overarching aim of his lab is to generate the knowledge critical to better vaccine design as well as to identify clinically meaningful biomarkers. In addition, his work attempts to establish the correlation between clinical responses and immunological changes in the course of immunotherapy. Most recently, in the area of immunological signatures for allergic disease, Dr. Wambre has identified a distinct immune cell subset involved in allergic disease (called TH2A) that is virtually absent in non-allergic individuals. He is currently examining the pathophysiologic meaning of this allergic T cell signature and whether these cells can be used as a potential therapeutic target in allergies.

CLOSE

Gideon Lack

Professor of Paediatric Allergy, King’s College London
Head of the Children’s Allergy Clinical Academic Group, King’s Health Partners Institute of Women and Children’s Health at Evelina London, Guy’s & St. Thomas’ NHS Foundation Trust

Gideon Lack is Professor of Paediatric Allergy at King’s College London and Head of the Academic Paediatric Allergy Service at Guy’s & St. Thomas’. He studied medicine at Oxford University before training as a Paediatrician in New York and specialised in Allergy at National Jewish Center in Denver, Colorado. He was Professor of Paediatric Allergy and Immunology at Imperial College London where he worked for 12 years before moving to King’s College London in 2006.

His research focuses on the prevalence of food allergies in children and the relationship between food allergies, eczema, and asthma. He works on novel immune-modulatory treatments for food allergies and on developing new strategies to prevent the development of allergies and asthma in children and adults.

The LEAP (Learning Early About Peanut allergy) study, published in the New England Journal of Medicine (2015) showed that early consumption of peanuts in atopic infants reduces the development of peanut allergy by >80%. In 2016-17 these findings were translated into changes in public health policy in the USA (National Institute of Allergy and Infectious Diseases, a division of the US Department of Health and Human Services, Addendum Guidelines for the Prevention of Peanut Allergy in the United States) and Australia. Recommendations to introduce peanut in children 4-6 months of age at high risk of developing peanut allergy.

Prof. Lack serves as a Member of Scientific Advisory Board at DBV Technologies S.A. He is a Member of the British Medical Association (BMA), The European Academy of Allergology and Clinical Immunology (EAACI) and the Royal College of Paediatrics and Child Health and a Fellow of the Academy of Medical Sciences.

CLOSE

Ian M Adcock

Dr Adcock is Professor of Respiratory cell & Molecular Biology at the National Heart & Lung Institute in Imperial College London. His research interests over the past 30 years include the regulation of the inflammatory mechanisms in severe asthma and COPD, understanding the causes of heightened inflammation and relative glucocorticoid insensitivity and defining markers that improve patient stratification to enable more effective targeted therapy.

In particular, he identified the major site of glucocorticoid receptor (GR) expression in asthma and defined key roles for AP-1, PI3K and p38 MAPK pathways in controlling steroid insensitivity in severe asthma and COPD. He also investigated how oxidative stress impacts upon the activation of these pathways and extended these studies to examine mitochondrial dysfunction and effects on metabolic repatterning and inflammasome activation in asthma and COPD. He was the first to study epigenetic processes in asthma and COPD and identified how epigenetics affect steroid function and airway inflammation especially through the identification of HDAC2 as being critical for some anti-inflammatory actions of GR. He was also involved in the first study of miRNAs in asthma and has subsequently studied their differential expression and function in primary human cells and in animal models of asthma and COPD and how this links with changes in gene expression and DNA methylation profiles.

More recently, he has taken a more systems medicine and bioinformatic approach to investigating severe asthma and COPD resulting in the assembly of the pan-European U-BIOPRED and the UK COPDMAP consortia. Bioinformatic and machine learning approaches indicated genes and pathways associated with relative steroid insensitive T2 asthma and distinct clinical features associated with activation of the IL-6 pathway, inflammasome activation, mitochondrial dysfunction and non-T2 pathways driving sputum eosinophilia. Ongoing investigations include longitudinal analysis of these identified pathways/clinical subtypes, eQTL analysis across multiple compartments and data fusion analysis. His research interests in asthma and COPD were recognized by the award of the ERS GOLD medal in COPD in 2019 and delivery of the Peter Macklem Lecture in 2018 on the systems analysis of severe asthma.

CLOSE

Sebastian L. Johnston

Sebastian L. Johnston: is a Professor of Respiratory Medicine & Allergy and Head of Airway Disease at the National Heart and Lung Institute, Imperial College London.

He is the Director of the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, is the Asthma UK Clinical Professor and is a former and current European Research Council Advanced Grant holder. He is Emeritus Senior Investigator at the National Institute of Health Research, UK.

He qualified from Guys Hospital in 1982, and completed his PhD from the University of Southampton in 1993. He became the Professor in 1999 when he moved to Imperial College London. He became a Fellow of the Royal College of Physicians, London in 2000, of the Royal Society of Biology in 2011, and of the Academy of Medical Sciences and the European Respiratory Society in 2014.

He edited Thorax from 2002-2010, and serves as Associate Editor or on the Editorial Boards of several other Respiratory and Allergy Journals. He has published >450 scholarly manuscripts in peer reviewed journals and has 18 patents. He has an h-index of 93, more than 42,000 lifetime citations with >10 manuscripts cited >500 each and >40 manuscripts cited >200 times each.

Notable discoveries that have emerged from his work include establishing the viral aetiology of the majority of asthma [1, 2] and COPD exacerbations [3], discovering novel mechanisms of susceptibility to virus infection in asthma [4, 5] and COPD, developing the first mouse model of rhinovirus infection [6], discovering novel mechanisms of disease [7, 8] and thereby, helping develop clinical trials investigating efficacy of novel treatment approaches for acute exacerbations of these diseases [9, 10].

REFERENCES
[1] Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DA. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310(6989): 1225-9.

[2] Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, Cunningham A, Robinson BS, Myint SH, Ward ME, Tyrrell DA, Holgate ST. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996; 154(3 Pt 1): 654-60.

[3] Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(9): 1618-23.

[4] Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, Davies DE. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201(6): 937-47.

[5] Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12(9): 1023-6.

[6] Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J, Tuthill TJ, Pedrick MS, Hurle MJ, Plumpton C, Sharp NA, Bussell JN, Swallow DM, Schwarze J, Guy B, Almond JW, Jeffery PK, Lloyd CM, Papi A, Killington RA, Rowlands DJ, Blair ED, Clarke NJ, Johnston SL. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 2008;14(2): 199-204.

[7] Beale J, Jayaraman A, Jackson DJ, Macintyre JDR, Edwards MR, Walton RP, Zhu J, Man Ching Y, Shamji B, Edwards M, Westwick J, Cousins DJ, Yi Hwang Y, McKenzie A, Johnston SL, Bartlett NW. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med 2014; 6(256): 256ra134.

[8] Toussaint M, Jackson DJ, Swieboda D, Guedán A, Tsourouktsoglou TD, Ching YM, Radermecker C, Makrinioti H, Aniscenko J, Edwards MR, Solari R, Farnir F, Papayannopoulos V, Bureau F, Marichal T, Johnston SL. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat Med. 2017 Jun;23(6):681-691.

[9] Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB; TELICAST Investigators. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006; 354(15): 1589-600.

[10] Johnston SL, Szigeti M, Cross M, et al. Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial. JAMA internal Medicine 2016;176:1630-7.

CLOSE

Bong-Seong Kim

Professor
Department of Pediatrics, GangNeung Asan Hospital, University of Ulsan College of Medicine

Academic Positions and Education

Professor, Department of Pediatrics, Division of Pediatric Allergy and Pulmonology, GangNeung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea (Mar. 2003 – present)

Research fellow, Pediatric Asthma Epidemiology Research Unit, Mayo clinic, Rochester, MN, United States (Sep. 2010 - Aug. 2011)

Fellowship, Department of Pediatrics, Division of Pediatric Allergy and Pulmonology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (Mar. 1999- Feb 2001)

Professional Affiliations and Academic Activities

The Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) ; Member of Pollen Study Group, Asthma Study Group for Preschool Children and Pneumonia and Respiratory Disease Study Group

The Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI) ; Member of Work Group for Rhinitis

Member of the COhort for Childhood Origin of Asthma and allergic diseases (COCOA) birth-cohort study group

Member of Editorial Board, the Allergy Asthma & Respiratory Disease journal (Allergy Asthma Respir Dis, AARD) [AARD (pISSN: 2288-0402, eISSN: 2288-0410) is an official publication of KAPARD and KAAACI]

Research Interest

• Epidemiology of Asthma and Allergic diseases
• Epidemiology of Pediatric Respiratory diseases

CLOSE